Small moleculeSleep & insomnia
- Primary research area
- Sleep · insomnia
- Regulatory status
- See formulation-specific sources
- Evidence level
- Human randomized trials
- Primary mechanism
- Z-drug hypnotic
Reference profile available · Coverage varies by sectionAlso known as Lunesta
What has been observed?
Selected source-linked reading notes, not the complete literature or a pooled conclusion.
Human · Abstract reviewedEszopiclone: what did the insomnia trial show?
788 adults aged 21–69 with primary insomnia were randomized to eszopiclone 3 mg (593 participants) or placebo (195) nightly for six months.
Patient reports of sleep onset, overnight wakefulness, sleep duration and quality improved versus placebo throughout follow-up. Daytime function ratings also improved. Unpleasant taste and headache were the most common adverse events.
Limits & adverse findings: This is a selected trial summary, not a full literature review or formal quality appraisal. Outcomes were reported through a voice-response system. No tolerance signal in this trial does not establish freedom from dependence or rare harms. Separate FDA warnings address serious complex sleep behaviors.
Open primary source · Read interpretation separatelyExplore outcomes for this compound- Uses & research
788 adults aged 21–69 with primary insomnia were randomized to eszopiclone 3 mg (593 participants) or placebo (195) nightly for six months. [1]
- Known half-life
No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.- Evidence & important limits
Outcomes were reported through a voice-response system. No tolerance signal in this trial does not establish freedom from dependence or rare harms. Separate FDA warnings address serious complex sleep behaviors. [1][2]
Safety & evidence boundaries
Source-specific information, not a personal safety clearance or monitoring plan.
Outcomes were reported through a voice-response system. No tolerance signal in this trial does not establish freedom from dependence or rare harms. Separate FDA warnings address serious complex sleep behaviors.
Human study: Outcomes were reported through a voice-response system. No tolerance signal in this trial does not establish freedom from dependence or rare harms. Separate FDA warnings address serious complex sleep behaviors. Source
Explore safety questions by system
These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.
Interactions, rare harms, long-term effects and reversibility require separate evidence. Do not infer they are absent when the sources here do not address them.
Identity, names & formulations
Canonical compound: Eszopiclone · eszopiclone
Searchable names: Lunesta
Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.
Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.
Understand the evidence types
Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.
- Randomized human trials
- Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
- Controlled human studies
- Use a comparison group; allocation and confounding still matter.
- Prospective human research
- Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
- Observational human research
- Describes associations. Confounding can explain differences.
- Case reports and series
- Useful for unusual events and safety signals, not reliable rates or effect sizes.
- Animal research
- Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
- Cell and tissue research
- Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
- Mechanistic and computational evidence
- Helps explain or predict a pathway; predictions need experimental and clinical testing.
- Anecdotal reports
- Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.
Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.